fda glp-1 compounding enforcement september 2025 to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads Compounded Semaglutide & Tirzepatide 2025:

The research demonstrated that treating these patients with a nebulized, multi-ingredient antioxidant agent containing NAC led to parallel increases in healthy T-cell cytokine production and a highly significant mean 54% reduction in self-reported symptom severity over several months

Global GLP-1 use is projected to top 100 million people by 2030

Unreconstituted powder lasts much longer than reconstituted solution

doi: 10.1016/j.jep.2024.118597 121 LuZ-HDingYWangY-JChenCYaoX-RYuanX-Met al

Today 10 (2), 139147

AHK-Cu's TGF-1 suppression appears to counteract this process, extending the growth phase without blocking DHT conversion directly like finasteride does